Aditxt, Inc. (ADTX)
| Market Cap | $399.19K+33.3% |
| Revenue (ttm) | $14.34K |
| Net Income | -$53.34M |
| EPS | $25450142.00 |
| Shares Out | 997.98M |
| PE Ratio | 0.00 |
| Forward PE | -0.00 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,762,594 |
| Open | $0.00 |
| Previous Close | $0.00 |
| Day's Range | $0.00 - $0.00 |
| 52-Week Range | $0.00 - $896.40 |
| Beta | n/a |
| Analysts | none |
| Price Target | n/a |
| Earnings Date | n/a |
About ADTX
Aditxt, Inc. focuses on discovery and development of biopharmaceutical products. The company develops AditxtScore and FlowSpot that enable individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It develops ADI-100 for skin grafting, psoriasis, and type-1 diabetes. In addition, the company provides Pearsanta that develops molecular tests based on the mitochondrial DNA (mtDNA) to develop tests for early detection of cancer; Mitomic targets mutations in mitochondrial DNA (mtDNA) to detect disease; Mitomic prostate test a blood-based assay that quantifies the level of the 3.4kb mtDNA deletion; and Mitomic endometriosis test, a blood-based assay that quantifies the level of one or more mtDNA deletions. Further, it offers Adivir for commercial development of products to address significant unmet needs in infectious disease and population health; and Adifem address critical unmet needs in women health. The company has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Mountain View, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
When insiders bought and sold
1 year · open-market trades onlyNot enough price history.
$ADTX stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in ADTX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ADTX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ADTX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New ADTX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ADTX from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from ADTX’s recent data — informational, not investment advice
